Loading...
01/11 03:09
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed outlook. Positive factors include revenue growth projections, international expansion, and community hubs. However, tariff pressures, reduced promotions, and unclear management responses on key metrics offset these positives. The Q&A section reveals concerns about margins and inventory. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
Net revenues Net revenues increased 8% year-over-year to $151.7 million, ahead of the outlook of flat to up 2%. This growth was driven by scrubwear growth, U.S. growth, and strong performance during business-as-usual selling periods.
Average order value (AOV) Average order value increased 6% to $114, primarily driven by higher average unit retail due to product mix and a higher rate of full-price sales.
Active customer growth Active customer growth remained consistent at 4%, pushing the active customer count to a company record of nearly 2.8 million. This growth occurred despite the promotional reset.
Net revenues per active customer Net revenues per active customer grew 2% year-over-year to $209, marking the first positive inflection in three years.
Scrubwear revenue Scrubwear revenue grew 8%, representing 84% of net revenues. Growth was supported by impactful color stories, strategic positioning in key styles, and effective merchandising and marketing.
Non-scrubwear revenue Non-scrubwear revenue increased 7%, representing 16% of net revenues. Growth was driven by strong performance in underscrubs, shoes, and the launch of ArchTek socks.
U.S. sales U.S. sales increased 8% to $127.3 million, marking the strongest performance over the past 9 quarters. Growth was balanced across new and repeat customers.
International net revenues International net revenues increased 12%, led by strong growth in new customers. However, reductions in promotional days impacted larger markets like Canada and Australia.
Gross margin Gross margin expanded 280 basis points to 69.9%, driven by lower discounts, improved return rates, lower duties, and reduced freight costs. These were partially offset by higher tariffs.
Adjusted EBITDA margin Adjusted EBITDA margin improved by 900 basis points to 12.4%, supported by SG&A leverage, efficiency efforts, and tariff mitigation strategies.
Net income Net income for the quarter was $8.7 million, compared to a net loss of $1.7 million in the prior year. This improvement reflects better overall financial performance.
Inventory Inventory increased 23% year-over-year to $151.2 million, driven by strategic investments in key styles and earlier timing of in-transit inventory.
New Fabric Solutions: Introduced FORMx and FIBERx fabrics, targeting specific needs like comfort, stretch, and durability. FIBERx will debut at the 2026 Winter Olympics.
Product Expansion: Launched ArchTek compression socks, the first patented medical-grade compression socks. Expanded head-to-toe solutions including outerwear, underscrubs, and footwear.
International Expansion: Expanded from 33 to nearly 60 international markets, including new entries in Japan, South Korea, and China (via Tmall). Focused on 'go broad' and 'go deep' strategies for market penetration.
Community Hubs: Opened 3 new stores in New York, Houston, and Chicago, with plans to accelerate store openings in 2026.
Revenue Growth: Achieved 8% year-over-year revenue growth in Q3, with U.S. sales up 8% and international sales up 12%.
Gross Margin: Gross margin improved to 69.9%, supported by reduced discounts, better returns processing, and lower freight costs.
Efficiency Improvements: Reduced SG&A expenses and optimized shipping and fulfillment operations, contributing to a 900 basis point improvement in adjusted EBITDA margin to 12.4%.
Promotional Strategy Reset: Reduced promotional activities to focus on full-price sales, leading to higher average order value and improved customer metrics.
Brand Engagement: Executed high-impact campaigns, including a viral Emmy Awards moment and global 'Where Do You Wear FIGS' campaign, enhancing brand visibility and emotional connection with healthcare professionals.
Tariff Headwinds: The company is facing growing tariff headwinds, particularly with added tariffs of 20% in Vietnam and 15% in Jordan, which are major production locations. This is expected to significantly impact gross margins in Q4 and beyond.
Inventory Management: Inventory levels have increased by 23% year-over-year, partly due to higher-than-planned in-transit inventory and deeper investments in key styles. This could lead to potential overstocking or inefficiencies in inventory management.
International Expansion Risks: The company is rapidly expanding into international markets, including Japan, South Korea, and China. While these markets present growth opportunities, they also carry risks related to localization, infrastructure investment, and market-specific challenges.
Promotional Strategy Reset: The company is undergoing a promotional strategy reset, which has impacted revenue growth in the short term. While the reset is expected to benefit long-term profitability, it poses risks to customer acquisition and retention during the transition.
Economic and Regulatory Uncertainties: The company operates in a global market and is exposed to economic and regulatory uncertainties, including potential changes in trade policies and healthcare regulations that could impact operations and costs.
Supply Chain Challenges: The company is working to optimize its supply chain, but higher tariffs and in-transit inventory issues highlight ongoing challenges that could disrupt operations or increase costs.
Emerging Growth Drivers: Investments in emerging growth drivers like community hubs, international teams, and new product categories carry execution risks and may not yield the expected returns in the short term.
Q4 2025 Revenue Growth: Expected to be the strongest net revenue growth of the year, driving full-year estimate to approximately 7% growth.
Adjusted EBITDA Margin Expectation: Increased above the high end of the original outlook, back to low double-digit levels for 2025.
Product Strategy Enhancements: Plans to elevate the product portfolio in 2026 and beyond with improved function and fit, expanded head-to-toe solutions, strategic inventory investments, and stronger calendar alignment.
New Fabric Solutions: Introduction of FIBERx fabric, set to debut in Milan at the 2026 Winter Olympics, designed for durability in demanding environments.
International Expansion: Rapid expansion from 33 to nearly 60 international markets by the end of 2025, with plans to debut in China through Tmall later this quarter.
Community Hubs: Three new stores planned for Q4 2025 in New York, Houston, and Chicago, with an accelerated cadence of openings in 2026.
Emerging Growth Drivers: Investments in international markets, teams, and community hubs expected to scale in importance in the years ahead.
2026 Revenue Growth: Commitment to growing the business in 2026, supported by strong current momentum and ongoing process improvements.
Tariff Mitigation Strategies: Plans to optimize costs across inbound and outbound shipping, fulfillment centers, and supplier negotiations to address tariff headwinds in 2026.
2026 Adjusted EBITDA Margins: Opportunity for adjusted EBITDA margins to be within range of current 2025 expectations despite ongoing tariff headwinds.
Dividend Program: No specific mention of a dividend program was made in the transcript.
Share Repurchase Program: The company did not repurchase shares this period and has $52 million available for future repurchases under the current share repurchase program.
The earnings call presents a mixed outlook. Positive factors include revenue growth projections, international expansion, and community hubs. However, tariff pressures, reduced promotions, and unclear management responses on key metrics offset these positives. The Q&A section reveals concerns about margins and inventory. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
The earnings call presents a mixed picture: a positive Q2 with revenue exceeding guidance and strong international growth, but cautious guidance for Q3 and 2025. The Q&A highlights concerns over tariffs, pricing, and reduced promotions impacting growth. The company prioritizes growth initiatives over share repurchases, indicating a conservative approach. Overall, the sentiment is neutral as positive elements are balanced by uncertainties and conservative guidance.
The earnings call presents a mixed picture: a slight revenue increase and active customer growth are positive, but declining margins, a flat gross margin outlook, and a net loss raise concerns. The Q&A reveals management's cautious approach to pricing amid tariff impacts and supply chain issues, suggesting limited short-term growth. The share repurchase program provides some support. Overall, the sentiment is neutral, as positive elements are offset by financial challenges and cautious guidance.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
